SecBot SecBot
8-K ·Filed Jun 12, 2026

BCRX

BIOCRYST PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago SEC0001171843-26-004096
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine approval of equity plan increase and director elections, no trading signal. The high shareholder support for say-on-pay (68.9% for) is notable but typical for this size company. Monitor the next 10-Q for actual share usage under the replenished plan.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.06
T+0 close · Jun 12, 2026 · via day close
Latest settled
−2.81%
T+60 · $8.81
Vs SPY
−3.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $9.06entry
  2. T+1 · 5mo ago −1.55%α −0.95% · $8.92
  3. T+5 · 5mo ago +0.88%α +2.27% · $9.14
  4. T+20 · 4mo ago +9.38%α +10.13% · $9.91
  5. T+60 · 2mo ago −2.81%α −3.82% · $8.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst held its 2026 Annual Meeting on June 11, 2026, where shareholders approved an amendment to the Stock Incentive Plan to increase shares available by 7 million, ratified Ernst & Young as auditor, and elected three directors. The plan amendment passed with 119.8 million votes for and 63.3 million against (65.4% approval of votes cast). This is a routine governance event with no material financial impact, as the additional shares simply replenish the equity compensation pool for future awards to employees and directors.

Key Facts

  • Shareholders approved an amendment to the Stock Incentive Plan to increase the number of shares available for issuance by 7,000,000 shares.
  • Total shares available under the Plan as of April 20, 2026, was 61,000,333 (including 46,287,133 already issued, 7,713,200 available, and the 7,000,000 increase).
  • Maximum shares issuable over the Plan's term is 88,090,000.
  • The Plan includes a 12-month minimum vesting period for awards (with exceptions for death, disability, or change in control, and for up to 5% of shares).
  • Each non-employee director is subject to an annual compensation cap of $750,000 ($1,000,000 for first-year directors).
  • The three director nominees (Theresa M. Heggie, Amy E. McKee, Jon P. Stonehouse) were elected with strong support (96-98% of votes cast in favor, excluding broker non-votes).
  • Ratification of Ernst & Young as independent auditor passed with 96.5% of votes cast in favor.
  • Advisory vote on executive compensation passed with 68.9% of votes cast in favor, though with significant opposition (31.1% against).

Financial Impact

No direct financial impact. The 7 million-share increase (approximately 3.2% of shares outstanding at current share count, assuming ~217M shares outstanding) expands the equity pool for future compensation grants but does not represent immediate dilution or cash cost.

dilution

Risk Factors

  • The Incentive Plan Proposal received 34.6% of votes cast against, indicating notable opposition from some shareholders.
  • Increased equity compensation could gradually dilute existing shareholders if large grants are made under the replenished share pool.
  • Advisory say-on-pay vote of 68.9% is below 70% threshold that some governance watchdogs consider a red flag, though not material.
  • Broker non-votes of 34 million (approx. 18% of outstanding) on the incentive plan and say-on-pay reflect passive institutional block.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-004096
Document: f8k_061226.htm0001171843-26-004096
Document: 0001171843-26-004096-index-headers.html0001171843-26-004096
Document: 0001171843-26-004096-index.html0001171843-26-004096
Document: 0001171843-26-004096.txt0001171843-26-004096

Track record

20 reports on BCRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026